Research: Leverage Proprietary Ingredients for GLP-1 Demographic

This research document explores how the rapid proliferation of glp-1-medications is driving a new consumer demographic with specific metabolic and gastrointestinal needs, and how beverage manufacturers are responding with proprietary biotics.

Key Findings

• The GLP-1 Microbiome Disruption: GLP-1 medications slow gastric emptying and disrupt the gut microbiome, leading to side effects like nausea and bloating. Consumers are seeking functional products to restore microbial balance and gut motility.
• Asahi’s Strategic Positioning: asahi-group-holdings, through asahi-group-foods, has developed lactobacillus-gasseri-cp2305, a heat-inactivated postbiotic proven to reduce anxiety and modulate the gut microbiome. Asahi has partnered with adm-wild-valencia to distribute this globally for use in adult-soft-drinks and snacks, specifically targeting the stressed, GLP-1-impacted demographic.
• Endogenous GLP-1 Secretion Hypothesis: Prebiotic sodas like olipop and poppi are currently undergoing clinical trials (NCT07105826) at texas-christian-university to test if their high fiber content ferments into short-chain fatty acids (SCFAs) that naturally stimulate endogenous-glp-1-secretion and enhance satiety without insulin spikes. This provides a physiological basis for the-diet-soda-paradox.
• The Fermentation Paradox: A critical formulation risk exists where prebiotic fibers, intended to improve gut health, cause gas and bloating during fermentation. This can temporarily exacerbate the exact gastrointestinal discomfort (nausea, delayed gastric emptying) that GLP-1 users are trying to resolve.
• Regulatory Hurdles: Brands must navigate strict FDA regulations and possess competent-and-reliable-scientific-evidence to avoid enforcement actions related to unapproved drug claims when marketing symptom relief to this demographic.